INTELLECTUAL PROPERTY AGREEMENTIntellectual Property Agreement • May 14th, 2020 • Premier Biomedical Inc • Biological products, (no disgnostic substances) • Pennsylvania
This Intellectual Property Agreement (this “Agreement”) is entered into on May 12, 2020 (“Effective Date”), concerning the pursuits set forth herein for the collective development, implementation and commercialization of a potential treatment for the COVID-19 virus and its effects on the human body (collectively referred to herein as the “Joint Venture”) by and between:
THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 14th, 2020 • Premier Biomedical Inc • Biological products, (no disgnostic substances)
This THIRD ADDENDUM TO EXCLUSIVE LICENSE AGREEMENT (this “First Amendment”) is made as of the 11th day of May, 2020, by and between Marv Enterprises, LLC a Limited Liability Company organized and existing under the laws of the Commonwealth of Pennsylvania (“Marv”) with an address of P.O. Box 1332, Hermitage, PA 16148 and Premier Biomedical, Inc.., a Nevada corporation with its principal business address at 1362 Springfield Church Road, Jackson Center, PA 16133 (“Licensee”).
TECHNOLOGY ACQUISITION AND FINANCING AGREEMENTTechnology Acquisition and Financing Agreement • May 14th, 2020 • Premier Biomedical Inc • Biological products, (no disgnostic substances) • Nevada
This Technology Acquisition and Financing Agreement (this “Agreement”) is entered into on May 12, 2020 (the “Effective Date”) for the collective acquisition, development, financing, implementation and commercialization of certain technologies that may be a potential treatment for the COVID-19 virus and its effects on the human body (collectively referred to herein as the “Joint Venture”) by and between:
